跳至主要内容
临床试验/CTRI/2022/01/039370
CTRI/2022/01/039370已完成未知

A randomized, double blind, placebo controlled, trial to determine the therapeutic efficacy of Ayush medicine NF2 in treatment of symptomatic COVID-19 patients along with standard allopathic treatment

Sriveda Sattva Private limited0 个研究点目标入组 100 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Hospitalized or in home isolation adult patient aged >18 years
  • Confirmed COVID-19 infection (RT ââ?¬â??PCR- Upper respiratory tract nasopharyngeal and oropharyngeal swab.
  • mild and moderate Symptomatic COVID 19 infection with or without comorbidities
  • Willingness to participate in the study
  • Indian nationals

排除标准

  • Age less than 18 years
  • Pregnancy and Lactation
  • Moribund state in which death is perceived to be imminent (ââ?°Â¤48 hours)
  • Patient not willing to participate in the study
  • Participation in any other clinical study

研究者

相似试验